IUPAC name
6,7-dichloro-1H,2H,3H,5H-imidazolidino[2,1-b]quinazolin-2-one
SMILES
ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
Compound class
Antithrombins; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers;
Therapeutic area
For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
Common name
Anagrelide
IUPAC name
6,7-dichloro-1H,2H,3H,5H-imidazolidino[2,1-b]quinazolin-2-one
SMILES
ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
INCHI
InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
FORMULA
C10H7Cl2N3O
Common name
Anagrelide
IUPAC name
6,7-dichloro-1H,2H,3H,5H-imidazolidino[2,1-b]quinazolin-2-one
Molecular weight
256.088
clogP
2.695
clogS
-3.743
HBond Acceptor
3
HBond Donor
1
Total Polar Surface Area
44.7
Number of Rings
3
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | SMILE | Frequency |
|---|---|---|---|---|
| FDBF00546 | 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one |
|
Clc1c2c(ccc1Cl)NC3=NC(=O)CN3C2 | 0.0003 |
